Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Brain cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jan 2019 Status changed from recruiting to completed.
- 30 Jan 2013 New trial record